Abstract:Human metapneumovirus (hMPV) is a leading cause of viral lower respiratory tract infection in children. The sole target of neutralizing antibodies targeting hMPV is the fusion (F) protein, a class I viral fusion protein mediating virus-cell membrane fusion. There have been several monoclonal antibodies (mAbs) isolated that neutralize hMPV; however, determining the antigenic sites on the hMPV F protein mediating such neutralizing antibody generation would assist efforts for effective vaccine design. In this report, the isolation and characterization of four new human mAbs, termed MPV196, MPV201, MPV314, and MPV364, are described. Among the four mAbs, MPV364 was found to be the most potent neutralizing mAb in vitro Binding studies with monomeric and trimeric hMPV F revealed that MPV364 had the weakest binding affinity for monomeric hMPV F compared to the other three mAbs, yet binding experiments with trimeric hMPV F showed limited differences in binding affinity, suggesting that MPV364 targets an antigenic site incorporating two protomers. Epitope binning studies showed that MPV364 targets antigenic site III on the hMPV F protein and competes for binding with previously discovered mAbs MPE8 and 25P13, both of which cross-react with the respiratory syncytial virus (RSV) F protein. However, MPV364 does not cross-react with the RSV F protein, and the competition profile suggests that it binds to the hMPV F protein in a binding pose slightly shifted from mAbs MPE8 and 25P13. MPV364 was further assessed in vivo and was shown to substantially reduce viral replication in the lungs of BALB/c mice. Overall, these data reveal a new binding region near antigenic site III of the hMPV F protein that elicits potent neutralizing hMPV F-specific mAbs and provide a new panel of neutralizing mAbs that are candidates for therapeutic development.IMPORTANCE Recent progress in understanding the human immune response to respiratory syncytial virus has paved the way for new vaccine antigens and therapeutics to prevent and treat disease. Progress toward understanding the immune response to human metapneumovirus (hMPV) has lagged behind, although hMPV is a leading cause of lower respiratory tract infection in children. In this report, we advanced the field by isolating a panel of human mAbs to the hMPV F protein. One potent neutralizing mAb, MPV364, targets antigenic site III on the hMPV F protein and incorporates two protomers into its epitope yet is unique from previously discovered site III mAbs, as it does not cross-react with the RSV F protein. We further examined MPV364 in vivo and found that it limits viral replication in BALB/c mice. Altogether, these data provide new mAb candidates for therapeutic development and provide insights into hMPV vaccine development.

Antiviral strategies against human metapneumovirus: Targeting the fusion protein

Neutralising antibodies against human metapneumovirus

Novel insights into the host cell glycan binding profile of human metapneumovirus

New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase

Prevalence of Human Metapneumovirus in Adults with Acute Respiratory Tract Infection in Beijing, China

Structure, immunogenicity, and conformation-dependent receptor binding of the post-fusion human metapneumovirus F protein

Epidemiology and Genetic Characterization of Human Metapneumovirus in Pediatric Patients from Hangzhou China

Antivirals targeting paramyxovirus membrane fusion

Structural basis for respiratory syncytial virus and human metapneumovirus neutralization

Human Metapneumovirus: Mechanisms and Molecular Targets Used by the Virus to Avoid the Immune System

A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein

Antibody Epitopes of Pneumovirus Fusion Proteins

Current developments and prospects on human metapneumovirus vaccines

Interferon-Mediated Response to Human Metapneumovirus Infection

Inhibition of Human Metapneumovirus Replication by Small Interfering RNA.

Host Components That Modulate the Disease Caused by hMPV

A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo

Characterization of the interaction domains between the phosphoprotein and the nucleoprotein of human Metapneumovirus

Protective efficacy of a novel recombinant influenza virus carrying partial human metapneumovirus F protein epitopes

Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus

Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer